In a market often dominated by macro noise and earnings volatility, Tribe Public’s latest CEO Presentation and Q&A Webinar Event offered something far rarer: a glimpse into the future of cancer treatment—and perhaps, a pathway to curing it.
The event, titled “Can Targeted Alpha Therapy Cure Cancer,” featured NAYA Therapeutics Founder and CEO Daniel Teper, who guided investors and attendees through a compelling vision of next-generation oncology innovation. The full event can be viewed here:
A New Frontier in Cancer
NAYA Therapeutics is not approaching cancer incrementally—it is aiming to eradicate residual disease entirely. At the center of this ambition lies a dual-platform strategy:
- Astatine-211 (²¹¹At) targeted alpha therapies
- NK-cell-engaging bifunctional antibodies
This combination is designed to deliver what many therapies struggle to achieve: deep and durable responses, particularly in difficult-to-treat cancers like hepatocellular carcinoma (HCC) and multiple myeloma.
Teper’s presentation struck a balance between scientific rigor and commercial realism—no small feat in a sector where optimism often outruns logistics.
The 7.2-Hour Problem—and Opportunity
If there was a quiet star of the discussion, it wasn’t just the science—it was the supply chain.
Targeted alpha therapies operate on a tight clock. Astatine-211, with its 7.2-hour half-life, leaves little room for error. Delays are not inconvenient; they are existential.
NAYA’s strategic insight is simple but powerful: treat logistics as a core competency, not a postscript.
- The company leverages bismuth-209, a naturally abundant precursor, enabling scalable production
- It emphasizes decentralized manufacturing, bringing production closer to patients
- It builds flexibility to support multiple indications without rebuilding infrastructure
In effect, NAYA is engineering reliability into a therapeutic category where timing is everything. It’s less “just-in-time” and more “just-in-survival.”
Pipeline with Purpose
NAYA’s early pipeline reflects this integrated strategy:
- NY-703 targeting hepatocellular carcinoma
- NY-738 focused on multiple myeloma
Both programs aim to capitalize on the precision of alpha radiation while minimizing collateral damage—a long-standing challenge in oncology.
The approach aligns clinical ambition with operational execution, a pairing that investors increasingly recognize as essential in radiopharmaceuticals.
Tribe Public’s Expanding Platform
The event also underscored Tribe Public’s growing role as a conduit between companies and capital.
For those unfamiliar, Tribe Public hosts global virtual events and in-person corporate sponsored events across 41 U.S. event venues, connecting:
- Institutional investors and family offices
- Portfolio managers and advisors
- Corporate executives and media professionals
The model blends efficient access with community-building—often over private meals at top-tier venues—creating an environment where conversations extend beyond the slide deck.
Learn more or join the community at www.tribepublic.com.
A Broader Lens: Innovation and Impact
While the webinar focused on cutting-edge oncology, it also fits into a broader narrative: the convergence of innovation, accessibility, and impact.
In a world where figures like MrBeast have redefined philanthropy through scale and visibility—funding surgeries, food access, and clean water—biotech companies like NAYA are pursuing impact at the molecular level. Different methods, same underlying ambition: solve hard problems at scale.
Final Take
Tribe Public’s latest event delivered more than a company presentation—it offered a case study in how science, logistics, and capital markets intersect.
If NAYA Therapeutics succeeds, it won’t just validate targeted alpha therapy—it will reinforce a larger lesson: in modern biotech, the supply chain can be just as innovative as the science itself.
The Sources
- Tribe Public – Official Website: https://tribepublic.comtribepublic
- Tribe Public – About / Event Platform Overview: https://tribepublic.com/abouttribepublic
- Tribe Public – Events Page (Past and Upcoming Events): https://tribepublic.com/eventstribepublic
- NAYA Therapeutics – Official Website: https://www.nayatx.comyoutube
- NAYA Therapeutics CEO Event Video – “Can Targeted Alpha Therapy Cure Cancer”: https://www.youtube.com/watch?v=XCtt3CedDA8youtube
- NAYA Therapeutics Expands HCC Pipeline – Press Coverage of Astatine-211 Programs: https://www.pharmiweb.com/press-release/2025-06-17/naya-therapeutics-expands-its-hepatocellular-carcinoma-hcc-pipeline-with-first-in-class-gpc3-targeted-astatine-211-alpha-radioimmunotherapypharmiweb
- NAYA Therapeutics Astatine-211 Partnership – NY-703 and Global Supply Chain: https://trial.medpath.com/news/e4c6693261bb40b5/naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-therapy-for-hepatocellular-carcinomatrial.medpath
- MrBeast Philanthropy Overview – Business Insider: https://www.businessinsider.com/mrbeast-philanthropybusinessinsider
- Beast Philanthropy and Global Partnerships – Rockefeller Foundation: https://www.rockefellerfoundation.org/news/beast-philanthropy-and-rockefeller-foundation-launch-strategic-partnershiprockefellerfoundation
- MrBeast and “Stunt Philanthropy” – Northeastern University Analysis: https://news.northeastern.edu/2023/11/27/mrbeast-stunt-philanthropynews.northeastern
